People: Orexigen Therapeutics Inc (OREX.OQ)
OREX.OQ on NASDAQ Stock Exchange Global Select Market
7.55USD
3:32pm EDT
7.55USD
3:32pm EDT
Price Change (% chg)
$0.01 (+0.20%)
$0.01 (+0.20%)
Prev Close
$7.54
$7.54
Open
$7.51
$7.51
Day's High
$7.66
$7.66
Day's Low
$7.46
$7.46
Volume
160,108
160,108
Avg. Vol
337,439
337,439
52-wk High
$7.84
$7.84
52-wk Low
$3.77
$3.77
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Eckard Weber |
2009 | Independent Chairman of the Board | |
Michael Narachi |
53 | 2009 | President, Chief Executive Officer, Director |
Joseph Hagan |
43 | 2011 | Acting Chief Financial Officer, Treasurer, Chief Business Officer |
Heather Turner |
39 | 2010 | Senior Vice President, General Counsel, Secretary |
Preston Klassen |
43 | 2009 | Head of Global Contrave Program, Senior Vice President - Product Development |
Dawn Viveash |
56 | 2009 | Senior Vice President - Regulatory Affairs |
Mark Booth |
52 | 2009 | Chief Commercial Officer |
Louis Bock |
2005 | Independent Director | |
Wendy Dixon |
57 | 2010 | Independent Director |
Brian Dovey |
71 | 2004 | Independent Director |
David Endicott |
48 | 2012 | Independent Director |
Peter Honig |
55 | 2010 | Independent Director |
Patrick Mahaffy |
49 | 2009 | Independent Director |
Lota Zoth |
53 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Eckard Weber |
Dr. Eckard Weber, M.D., is Independent Chairman of the Board of Orexigen Therapeutics Inc. He is one of co-founders and has served as a member of board of directors since inception in September 2002, and as the chairman of board of directors since March 2004. From November 2008 to March 2009, Dr. Weber served as interim President and Chief Executive Officer. Dr. Weber is also a Partner at Domain Associates, L.L.C. a position he has held since 2001. Dr. Weber currently serves as interim chief executive officer of Sonexa Therapeutics. He is chairman of the board at Ascenta Therapeutics Inc, Ocera Therapeutics Inc, Sequel Pharmaceuticals Inc, Tobira Therapeutics Inc. and Tragara Pharmaceuticals Inc. Dr. Weber was chairman of Peninsula Pharmaceuticals, Inc, chairman of Cerexa Inc., chairman of NovaCardia, Inc. chairman of Calixa Therapeutics until the company was sold to Cubist Pharmaceuticals in December 2009 and a board member of Conforma Therapeutics Corporation and Cabrellis Pharmaceuticals Corporation until they were sold to Biogen-IDEC, Inc. and Pharmion Corporation, respectively. In the past five years, Dr. Weber has also served as a member of the board of directors of Novacea Inc. Dr. Weber holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany. Board member of Acea Pharmaceuticals Inc., Ascenta Therapeutics Inc., Calixa Therapeutics Inc., Cytovia Inc., Domain AntiBacterial Acquisition Corporation, Ocera Therapeutics Inc., Sonexa Therapeutics Inc. Syndax Pharmaceuticals Inc. Tobira Therapeutics Inc. and Tragara Pharmaceuticals Inc. Dr. Weber also has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. Until 1995, he was a tenured Professor of Pharmacology at the University of California, Irvine. Dr. Weber is the inventor or co-inventor of over 40 patents and patent applications and has published over 130 papers in scientific periodicals. |
Michael Narachi |
Mr. Michael A. Narachi is President, Chief Executive Officer and Director of Orexigen Therapeutics Inc., March 31, 2009. Previously, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a therapeutics company, where he served as General Manager of Amgen’s Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He currently serves on the board of directors of Amag Pharmaceuticals, Inc., a publicly traded pharmaceutical company. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles. |
Joseph Hagan |
Mr. Joseph P. Hagan is Acting Chief Financial Officer, Treasurer, Chief Business Officer of Orexigen Therapeutics Inc. He is Chief Business Officer since June 2011 and acting-Chief Financial Officer since March 2011. From May 2009 to June 2011 Mr. Hagan served as Senior Vice President, Corporate Development, Strategy, Communications. Previously, from May 2008 to May 2009, Mr. Hagan established and was a Partner at Groundswell Advisors, a biotechnology consulting firm, providing operational guidance and execution in corporate strategy, commercialization, financing and partnership opportunities. While at Groundswell Advisors, he served as acting chief executive officer of Unity Pharma, consulted to numerous small biotech companies, and served on the board of directors of Seredigm Corp. Prior to establishing Groundswell, from September 1998 to April 2008, Mr. Hagan worked for Amgen Inc. where he served in various senior business development roles and also he served as a director on the boards of directors of six portfolio companies. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego. |
Heather Turner |
Ms. Heather D. Turner is Senior Vice President, General Counsel and Secretary of Orexigen Therapeutics Inc. She has held these positions since May 2010. From June 2007 to May 2010, Ms. Turner served as Vice President, General Counsel and Secretary. Previously, from July 2005 to June 2007, Ms. Turner worked first as Corporate Counsel and most recently as Associate General Counsel at Conor Medsystems, LLC (previously Conor Medsystems, Inc.), in Menlo Park, California, a company specializing in drug-eluting stents. From 1999 until 2005, Ms. Turner was an associate at Cooley LLP (formerly Cooley Godward Kronish LLP), a national law firm, where she advised public and private companies, investors and board members. At both Conor Medsystems and Cooley, Ms. Turner advised on matters ranging from public reporting, public offerings, securities law compliance, mergers and acquisitions, commercial and development contracts, corporate governance, board and committee duties and other general corporate matters. Ms. Turner has a B.A. from U.C. Santa Barbara and a J.D. from UCLA School of Law. |
Preston Klassen |
Dr. Preston Klassen, M.D., M.H.S., is Head of Global Contrave Program and Senior Vice President - Product Development of Orexigen Therapeutics Inc., since November 2009. Prior to joining Orexigen, from June 2002 to November 2009, Dr. Klassen worked at Amgen, most recently serving as the Therapeutic Area Head for Nephrology and Executive Medical Director, where he led global development efforts for the company’s renal franchise. While at Amgen, Dr. Klassen oversaw Phase 2-4 clinical activity for products addressing renal, diabetes and other metabolic diseases. Dr. Klassen’s experience includes global regulatory filings, including NDA and sNDA submissions, development and execution of several cardiovascular outcomes trials, and oversight of clinical commercialization activities for multiple marketed products, including EPOGEN®, Aranesp®, and Sensipar®. Dr. Klassen played a lead role in regulatory interactions related to the benefit/risk profile of erythropoietin stimulating agents for renal indications, including presenting at a 2007 joint meeting of the FDA Cardiovascular and Renal Drugs and the Drug Safety and Risk Management Advisory Committees. Prior to joining Amgen, from July 1997 to June 2002, Dr. Klassen was a faculty member in the Division of Nephrology at Duke University Medical Center in North Carolina. Dr Klassen received his M.D. from the University of Nebraska College of Medicine and completed his residency in Internal Medicine, fellowship in Nephrology, and M.H.S. degree at Duke University. |
Dawn Viveash |
Dr. Dawn Viveash, M.D., is Senior Vice President - Regulatory Affairs of Orexigen Therapeutics Inc., since November 2009. Dr. Viveash has over 20 years of experience in the biopharmaceutical industry, across all stages of development and product commercialization. Prior to joining Orexigen, from November 2006 to November 2009, Dr. Viveash was Vice President of Regulatory Affairs and Safety, at Amylin Pharmaceuticals where she managed regulatory affairs and the safety department for a product portfolio that included the company’s obesity and diabetes pipeline. Prior to her role at Amylin Pharmaceuticals, Dr. Viveash was Vice President of Regulatory Affairs and Safety at Amgen, and from January 2000 to July 2002, was Vice President of Regulatory Affairs, Safety and Professional Services at Immunex Corporation. While serving in leadership roles at Amylin, Amgen and Immunex, Dr. Viveash oversaw a number of NDA and BLA submissions along with corresponding global regulatory submissions; her experience includes products such as Enbrel®, Aranesp®, Sensipar®, Kepivance® and Byetta®. Dr. Viveash has participated in several FDA Advisory Committees and has been involved in regulatory discussions regarding a variety of post marketing safety issues. Dr. Viveash holds a B. Pharmacy First Class, London School of Pharmacy, England, a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.), University College Hospital, London, UK, and is a Member of the Royal College of Physicians, London, UK. |
Mark Booth |
Mr. Mark D. Booth is Chief Commercial Officer of Orexigen Therapeutics Inc., since August 24, 2009. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently, Mr. Booth served as President of Takeda Pharmaceuticals North America (TPNA) from October 2001 to June 2008, where he presided over the commercial, medical and scientific affairs, business development and all support functions. Prior to his role at TPNA, Mr. Booth served as Senior Vice President, General Manager at Immunex Corporation from January 2000 to September 2001, where he was responsible for the sales, marketing and project management functions. Before joining Immunex Corporation, Mr. Booth was at Abbott Laboratories from 1983 to 2000, where he served in a range of leadership positions including Division Vice President, General Manager for the anti-infective franchise. Mr. Booth holds a BS in Biology from Northern Illinois University and an M.B.A from Northwestern University Kellogg School of Management. |
Louis Bock |
Mr. Louis C. Bock is Independent Director of Orexigen Therapeutics Inc. Mr. Bock has served as a member of board of directors since April 2005. Mr. Bock is a Managing Director of Scale Venture Partners, a venture capital firm. Mr. Bock joined Scale Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company where he worked from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves as a director of the following publicly traded companies: Horizon Therapeutics, Inc., for which he also serves as a member of the audit and compensation committees, and Zogenix, Inc., for which he also serves as a member of the audit committee. In addition, Mr. Bock serves on the board of directors of the following privately-held companies: Ascenta Therapeutics, Inc., for which he also serves as a member of the audit committee, and Sonexa Therapeutics, Inc., and also serves on the board of directors of Arizona Technology Enterprises, LLC, a non-profit organization. Mr. Bock is responsible for Scale Venture Partners’ investment in Somaxon Pharmaceuticals, Inc. In the past five years, Mr. Bock has also served as a member of the boards of directors of the following publicly traded companies: diaDexus Inc. and SGX Pharmaceuticals, Inc. Mr. Bock received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco. He is a member of audit and nominating/corporate governance committees. |
Wendy Dixon |
Dr. Wendy L. Dixon, Ph.D., is Independent Director of Orexigen Therapeutics Inc. She has served as a member of board of directors since April 20, 2010. From December 2001 to May 2009, Dr. Dixon was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb Company, and served on the CEO’s Executive Committee. From 1996 to 2001, she was Senior Vice President, Marketing — USHH at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, Inc. and Centocor, Inc. and various positions at SmithKline & French Pharmaceuticals (now GSK) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon serves on the board of directors of Alkermes plc., Ardea Biosciences, Inc., Furiex Pharmaceuticals, Inc. and Incyte Corporation. In the past five years, Dr. Dixon has also served as a member of the board of directors of DENTSPLY International, a publicly traded company, and is a senior advisor for The Monitor Group, a Global Consulting Firm. Dr. Dixon received her MSc and BSc in Natural Science and her Ph.D. in Biochemistry from University of Cambridge. Dr. Dixon has a 30 year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and launching and growing more than 20 pharmaceutical products including Tagamet®, Fosamax®, Singulair®, Plavix®, Abilify®, Reyataz® and Baraclude®. |
Brian Dovey |
Mr. Brian H. Dovey is Independent Director of Orexigen Therapeutics Inc., since January 2004. Mr. Dovey has been a Partner of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, since 1988. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now part of sanofi-aventis), including as president from 1986 to 1988. Previously, Mr. Dovey was president of Survival Technology, Inc., a start-up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation and New York Telephone Company. Mr. Dovey has served as both president and chairman of the National Venture Capital Association. He is Chair of the Wistar Institute, a non-profit preclinical biomedical research company. Mr. Dovey serves on the board of directors and is also Chairman at the Center for Venture Education (Kauffman Fellows Program). He was also a former board member of the industry associations representing the medical device industry as well as the association representing consumer pharmaceuticals. In the past five years, Mr. Dovey has also served as a member of the board of directors of the following publicly traded companies: Align Technology, Inc., Cardiac Science, Inc. and Neose Technologies, Inc. Mr. Dovey received his B.A. from Colgate University and an M.B.A. from the Harvard Business School. Mr. Dovey has experience in the life sciences industry through Domain’s venture capital investments. Through his membership on over 35 private and public companies’ boards of directors over the years, he also has developed experience in corporate governance and other leadership matters. His past experience as President of Rorer Group and Survival Technology further exemplifies his operational, strategic and corporate leadership experience. He is chairman of compensation committee. |
David Endicott |
Mr. David Endicott has been appointed as Independent Director of Orexigen Therapeutics Inc., effective November 29, 2012. Mr. Endicott brings over 25 years of pharmaceutical and healthcare experience serving leadership roles in the U.S. and internationally at Allergan, Inc. He currently serves as President of Allergan Medical, Asia Pacific and Latin America. Prior to this he served in roles as President, Allergan Medical and President of Europe, Middle East and Africa. Mr. Endicott has led Allergan's U.S. Specialty Pharmaceuticals business, and established Allergan's Managed Markets group in addition to other leadership roles since joining Allergan in 1986. |
Peter Honig |
Dr. Peter K. Honig, M.D., is Independent Director of Orexigen Therapeutics Inc. He has served as a member of board of directors since February 26, 2010. Dr. Honig currently serves as the Head of Global Regulatory Affairs at AstraZeneca, Inc. Prior to this position, from January 2003 through December 2009, Dr. Honig served as Senior Vice President, Worldwide Regulatory Affairs and Product Safety at Merck & Company. From March 2002 to January 2003, Dr. Honig was Merck’s Vice President, Worldwide Product Safety and Quality Assurance. Prior to Merck, from 1993 to 2002, Dr. Honig held various positions at the FDA including Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research. Dr. Honig received his B.A. in History from Columbia College of Columbia University, his M.D. from Columbia College of Physicians & Surgeons and his M.P.H from Columbia University School of Public Health. Dr. Honig has over 15 years of experience in the drug industry, including nine years at the FDA, specifically in research and development, regulatory affairs and product safety. He has served in various leadership roles in the American Society of Clinical Pharmacology and Therapeutics, including President, Vice President and member of the Board of Directors. His is also the current PhRMA representative to the International Conference on Harmonization Steering Committee. |
Patrick Mahaffy |
Mr. Patrick J. Mahaffy is Independent Director of Orexigen Therapeutics Inc., since February 2009. Mr. Mahaffy is a founder of Clovis Oncology, Inc. and has served as President and Chief Executive Officer and a member of its board of directors since its inception. Previously, Mr. Mahaffy served in the same role at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the board of directors of Flexion Therapeutics, Inc. He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University. Mr. Mahaffy has operational, management and leadership experience in the biotechnology industry. Over the past 16 years, he co-founded, built and sold two companies. Through this past experience, Mr. Mahaffy has developed a background in drug development, including experience with the U.S. Food and Drug Administration’s, or FDA’s, and the European Medicines Agency’s approval process and the post-approval commercialization process in the US and Europe. He has recently started his third oncology focused company, Clovis Oncology. |
Lota Zoth |
Ms. Lota S. Zoth, CPA, is Independent Director of Orexigen Therapeutics Inc., since April 27, 2012. Ms. Zoth served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. from April 2004 to July 2007 and also served as its Controller and Principal Accounting Officer. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporate Controller and Principal Accounting Officer at PSINet Inc., Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth is a member of the board of directors of two private companies. Ms. Zoth received a B.B.A. in accounting from Texas Tech University. She is chairman of audit committee. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Eckard Weber |
46,726 |
Michael Narachi |
5,765,770 |
Joseph Hagan |
2,068,540 |
Heather Turner |
2,292,280 |
Preston Klassen |
2,141,190 |
Dawn Viveash |
1,088,830 |
Mark Booth |
1,661,340 |
Louis Bock |
-- |
Wendy Dixon |
-- |
Brian Dovey |
-- |
David Endicott |
-- |
Peter Honig |
-- |
Patrick Mahaffy |
-- |
Lota Zoth |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Eckard Weber |
0 | 0 |
Michael Narachi |
0 | 0 |
Joseph Hagan |
0 | 0 |
Heather Turner |
0 | 0 |
Preston Klassen |
0 | 0 |
Dawn Viveash |
0 | 0 |
Mark Booth |
0 | 0 |
Louis Bock |
0 | 0 |
Wendy Dixon |
0 | 0 |
Brian Dovey |
0 | 0 |
David Endicott |
0 | 0 |
Peter Honig |
0 | 0 |
Patrick Mahaffy |
0 | 0 |
Lota Zoth |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
BOOTH MARK D |
20,000 | $7.50 |
HAGAN JOSEPH P |
10,000 | $1.66 |
BOOTH MARK D |
15,722 | $7.25 |
HAGAN JOSEPH P |
10,000 | $7.40 |
BOOTH MARK D |
29,045 | $7.75 |
BOOTH MARK D |
64,767 | $1.66 |
KLASSEN PRESTON |
71,229 | $7.16 |
KLASSEN PRESTON |
71,229 | $1.66 |
KLASSEN PRESTON |
28,771 | $1.66 |
HAGAN JOSEPH P |
28,000 | $7.00 |
HAGAN JOSEPH P |
28,000 | $1.66 |
KLASSEN PRESTON |
28,771 | $7.21 |
BOOTH MARK D |
27,685 | $1.66 |
BOOTH MARK D |
27,685 | $6.67 |
BOOTH MARK D |
100 | $6.68 |
BOOTH MARK D |
22,315 | $1.66 |
BOOTH MARK D |
22,215 | $6.67 |
NARACHI MICHAEL A |
25,762 | $7.66 |
NARACHI MICHAEL A |
124,238 | $7.66 |
TURNER HEATHER D |
82,433 | $7.68 |
NARACHI MICHAEL A |
25,762 | $1.70 |
TURNER HEATHER D |
82,433 | $1.66 |
NARACHI MICHAEL A |
124,238 | $1.66 |
HAGAN JOSEPH P |
30,000 | $1.66 |
NARACHI MICHAEL A |
147,100 | $1.66 |

